Loading…
Spero Therapeutics, Inc. is projected to rise to $2.87 by 2027, a +35% move from its current price of $2.12. SPRO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.04 | $2.12 | $2.21 | 0.00% |
| Jul 14 | $2.00 | $2.12 | $2.24 | -0.01% |
| Jul 15 | $1.98 | $2.12 | $2.27 | -0.01% |
| Jul 16 | $1.96 | $2.12 | $2.30 | -0.01% |
| Jul 17 | $1.94 | $2.12 | $2.32 | -0.01% |
| Jul 18 | $1.92 | $2.12 | $2.34 | -0.02% |
| Jul 19 | $1.91 | $2.12 | $2.36 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.91 | $2.12 | $2.36 | -0.02% |
| Week 2 | $1.82 | $2.12 | $2.46 | -0.04% |
| Week 3 | $1.76 | $2.12 | $2.54 | -0.06% |
| Week 4 | $1.71 | $2.12 | $2.62 | -0.08% |
| Week 5 | $1.67 | $2.12 | $2.68 | -0.10% |
| Week 6 | $1.63 | $2.12 | $2.74 | -0.12% |
| Week 7 | $1.60 | $2.12 | $2.80 | -0.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
The company has license agreements with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc.
was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SPRO is a healthcare stock currently priced at $2.26 with a market capitalization of $130.86M and a market ranking of 4051. The stock’s near-term setup shows a range around the current price, with a neutral technical bias today.
A major floor 33.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 40.6% above — a clean break opens room to run.
A major ceiling 56.9% above — clearing it would confirm fresh momentum.
Key SPRO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SPRO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.15 | Sell | $2.14 | Sell |
| MA 10 | $2.19 | Sell | $2.18 | Sell |
| MA 20 | $2.30 | Sell | $2.29 | Sell |
| MA 50 | $2.52 | Sell | $2.44 | Sell |
| MA 100 | $2.50 | Sell | $2.46 | Sell |
| MA 200 | $2.41 | Sell | $2.36 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.64 | Neutral |
| Stoch RSI (14) | 46.53 | Neutral |
| CCI (20) | -65.45 | Neutral |
| Williams %R (14) | -66.67 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -2.33 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 33.33 | Neutral |
| TRIX (15) | -0.76 | Sell |
| Awesome (5,34) | -0.35 | Sell |
| Ultimate (7,14,28) | 23.44 | Buy |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 2.11 | Buy |
| ADX (14) | 19.10 | Neutral |
| ATR (14) | 0.08 | Info |
Technically, the picture is neutral with an RSI of 40. The SMA for 50 days sits at $2.62 while the 200-day SMA is $2.40. On the chart, near-term support is listed at $2.02 and resistance at $2.98. The 30-day price range spans from $1.60 to $3.19 and annualized volatility stands at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.02 | $2.12 | $2.72 | 0% | Neutral | |
| $2.19 | $2.87 | $4.04 | +35% | Bullish | |
| $2.08 | $2.85 | $4.23 | +35% | Bullish | |
| $1.98 | $2.81 | $4.33 | +33% | Bullish | |
| $2.06 | $3.02 | $4.80 | +42% | Bullish | |
| $2.04 | $3.08 | $5.04 | +45% | Bullish | |
| $2.72 | $4.24 | $7.11 | +100% | Bullish | |
| $3.06 | $4.88 | $8.38 | +130% | Bullish | |
| $2.84 | $4.65 | $8.15 | +119% | Bullish | |
| $2.96 | $4.97 | $8.88 | +134% | Bullish | |
| $4.23 | $7.96 | $15.41 | +276% | Bullish | |
| $6.44 | $14.30 | $31.01 | +575% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.02 | $2.12 | $2.56 | +0.00% |
| August 2026 | $1.72 | $2.06 | $2.55 | -2.87% |
| September 2026 | $1.75 | $2.11 | $2.66 | +2.68% |
| October 2026 | $1.78 | $2.17 | $2.76 | +2.49% |
| November 2026 | $1.71 | $2.09 | $2.70 | -3.32% |
| December 2026 | $1.69 | $2.09 | $2.72 | -0.25% |
Click any year to see its month-by-month SPRO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SPRO is projected to trade between $2.02 and $2.72, averaging $2.12 — a potential gain of 0% from today's $2.12. A consolidation phase looks the most probable path here.
Spero Therapeutics, Inc.'s 2027 outlook centres on $2.87, within a $2.19 to $4.04 range. That is up +35% on the projected 2026 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2028, SPRO could reach as high as $4.23, with a base case around $2.85 and support toward $2.08 — roughly +35% from $2.12. Buyers look set to stay in control over this stretch.
Expect SPRO to range from $1.98 to $4.33 through 2029. The $2.81 average target implies a +33% move from current prices. That is -1% versus the projected 2028 average. Momentum favours further upside here.
The SPRO price prediction for 2030 points to an average of $3.02 (low $2.06, high $4.80) — a potential gain of +42% on today's $2.12. Buyers look set to stay in control over this stretch.
In 2031, SPRO is projected to trade between $2.04 and $5.04, averaging $3.08 — a potential gain of +45% from today's $2.12. That is up +2% on the projected 2030 average. Momentum favours further upside here.
Spero Therapeutics, Inc.'s 2032 outlook centres on $4.24, within a $2.72 to $7.11 range. That is up +37% on the projected 2031 average. That marks a +100% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SPRO could reach as high as $8.38, with a base case around $4.88 and support toward $3.06 — roughly +130% from $2.12. Momentum favours further upside here.
Expect SPRO to range from $2.84 to $8.15 through 2034. The $4.65 average target implies a +119% move from current prices. That is -5% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The SPRO price prediction for 2035 points to an average of $4.97 (low $2.96, high $8.88) — a potential gain of +134% on today's $2.12. Momentum favours further upside here.
In 2040, SPRO is projected to trade between $4.23 and $15.41, averaging $7.96 — a potential gain of +276% from today's $2.12. That is up +60% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Spero Therapeutics, Inc.'s 2050 outlook centres on $14.30, within a $6.44 to $31.01 range. That is up +80% on the projected 2040 average. That marks a +575% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SPRO today (≈ 471.698113 SPRO) could be worth
$6,746.29
+$5,746.29 (+575%) by 2050 · US Dollar
Based on the average projected SPRO price of $14.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SPROwould be worth at today's price.
$1,000 invested in SPRO on Jul 10, 2025 (≈ 352.112687 SPRO) would be worth
$746.48
-$253.52 (-25.4%) today · 0.75× · US Dollar
Based on a SPRO entry price of $2.84 vs. today's $2.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.2 | $963.64 | -3.6% |
| 1 month ago | $2.54 | $834.65 | -16.5% |
| 3 months ago | $2.67 | $794.01 | -20.6% |
| 6 months ago | $2.51 | $844.62 | -15.5% |
| 1 year ago | $2.84 | $746.48 | -25.4% |
| All time (5.0y) ago | $14.34 | $147.84 | -85.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SPRO forecast.
Our base-case forecast reaches $4.20 around 2032.
Implied market cap at $4.20: $243.19M
The multi-year forecast portrays a bullish trajectory after 2026, with the average price rising from $2.26 in 2026 to higher levels in subsequent years. Notably, 2027 shows an average of $3.21 with a 42.2% ROI and bullish sentiment, followed by 2028 at $3.01 (33.1% ROI) and 2029 at $2.94 (30.3% ROI). By 2030 the average is projected at $3.15 with a 39.3% ROI and bullish sentiment, continuing through 2031 ($3.08, 36.5%), 2032 ($4.72, 108.7%), 2033 ($5.38, 138.2%), 2034 ($4.82, 113.1%), and 2035 ($5.43, 140.2%).
The forecast for 2040 shows $8.44 (273.6% ROI) and for 2050 $15.90 (603.5% ROI), both labeled bullish. Drivers referenced in the forecast include continued progress in Tebipenem HBr development, licensing deals, and ongoing clinical efforts, while risks reflect the inherent uncertainties of clinical-stage biotech and market fluctuations.
Tap a question to reveal the answer.
2030 avg price is $3.15, with a min of $1.96 and a max of $5.43; ROI is 39.3% and sentiment is BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising averages and notable upside by 2032–2050 (for example, 2032 avg $4.72, ROI 108.7%; 2040 avg $8.44, ROI 273.6%; 2050 avg $15.90, ROI 603.5%), though results are not guaranteed and depend on future developments.
Yes. The forecast shows maximum values that exceed $10 in years such as 2033 ($10.16) and 2035 ($10.74), with other years also reaching higher highs.
Current price is $2.26 and market capitalization is $130.86M.
The 30-day picture is neutral with RSI 40. The SMA50 is $2.62 and the SMA200 is $2.40. Near-term support is $2.02 and resistance is $2.98, with a 30-day range of $1.60 to $3.19.
Spero Therapeutics, Inc. Community Discussion
0Share your Spero Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.